Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 20/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.35 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21386670 | 0.87 | FGFR4 (0.47) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL21386682 | 0.84 | EGFR (0.42) | FGFR4FGFR1 | |
| SCHEMBL21756559 | 0.82 | FGFR1 (0.50) | FGFR4FGFR1 | |
| SCHEMBL21756545 | 0.77 | FGFR4 (0.38) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL21756558 | 0.76 | FGFR1 (0.39) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL21756608 | 0.75 | FGFR4 (0.39) | FGFR4FGFR1FGFR2FGFR3RPS6KB2 | |
| SCHEMBL18131697 | 0.73 | FGFR4 (0.40) | FGFR4FGFR1FGFR2FGFR3RPS6KB2 | |
| SCHEMBL21756544 | 0.73 | FGFR1 (0.38) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL21756547 | 0.72 | FGFR4 (0.61) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL22451238 | 0.72 | FGFR4 (0.32) | FGFR4FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008292-B2 | FGFR4 inhibitor and preparation method and use thereof | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2021-05-18 | — | — | US | disclosed |
| EP-3543227-B1 | FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2020-12-30 | — | — | EP | disclosed |
| US-20200062716-A1 | FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2020-02-27 | — | — | US | disclosed |
| EP-3543227-A1 | FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Guangdong Zhongsheng Pharmaceutical Co., Ltd (CN) | 2019-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008292-B2 | FGFR4 inhibitor and preparation method and use thereof | FGFR4, FGFR1, FGFR2 | FGFR4 1/4885FGFR1 2/4885FGFR2 3/4885 |
| US-20200062716-A1 | FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | FGFR4, FGFR1, FGFR2 | FGFR4 1/4885FGFR1 2/4885FGFR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.